The cost of antiemetic therapy for chemotherapy-induced nausea and vomiting in patients receiving platinum-containing regimens in daily practice in Japan: A retrospective study

Shota Hamada, Shiro Hinotsu, Katsuhito Hori, Hiroshi Furuse, Takehiro Oikawa, Junichi Kawakami, Seiichiro Ozono, Hideyuki Akaza, Koji Kawakami

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose The objective of this study was to estimate the cost of antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in daily practice in Japan. Methods This was a retrospective observational study using medical records. Eligible patients were those with bladder or testicular cancer receiving platinum-containing highly emetogenic chemotherapy. The incidence of CINV on days 1-5 in single-day chemotherapy and on days 1-9 in multiple-day chemotherapy, and the costs of antiemetic therapy directly associated with the administration of antiemetics were estimated. The analysis of costs was performed from a hospital perspective. Results A total of 54 patients or 169 chemotherapy courses were included. In all chemotherapy courses 5- HT 3 receptor antagonists were used on the day(s) that platinum-containing agents were administered and frequently used on subsequent days. In contrast, the use of corticosteroids was infrequent. Acute CINV in single-day chemotherapy was well controlled, but the incidences of delayed CINV in single-day chemotherapy and CINV in multiple-day chemotherapy were relatively high. The costs for antiemetic therapy were $484.65 in courses with CINV and $318.56 in courses without CINV, and the difference was approximately $170 per chemotherapy course, which was considered to be mainly imputable to the prevalence of CINV. Conclusions The cost of antiemetic therapy for CINV is substantial in Japan as well as in other countries, and it is suggested that the onset of CINV is a possible cost driver. The improvements in antiemetic therapy may contribute not only to improved patient well-being but also to a reduction of economic burden.

Original languageEnglish
Pages (from-to)813-820
Number of pages8
JournalSupportive Care in Cancer
Volume20
Issue number4
DOIs
Publication statusPublished - Apr 2012

Keywords

  • Chemotherapy-induced nausea and vomiting
  • Cost of illness
  • Emesis
  • Health economics
  • Pharmacoeconomics

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'The cost of antiemetic therapy for chemotherapy-induced nausea and vomiting in patients receiving platinum-containing regimens in daily practice in Japan: A retrospective study'. Together they form a unique fingerprint.

  • Cite this